20+ years experience as leader in global drug development and commercialization, currently Chief Development Officer at Kaléo Pharma. 

Experience across multiple therapeutic areas including Endocrine Disorders, Anti-infectives, Antivirals, Central Nervous System Disorders (Schizophrenia, Bipolar Disorders, Generalized Anxiety Disorders, Major Depression, Migraine, Anesthesia), Women’s Health, as well as a number of orphan indications

Board Director in private and public-sector companies

Doctor of Philosophy (Ph.D.), Biochemistry and Molecular Biology, University of Medicine and Dentistry of New Jersey

• 

  Board of Director in GoodCap

  A life sciences company developing psilocybin-based therapeutics